Skip to Content
Cancer Diagnosis Program
Contact NExT
Show menu
Search this site
Last Updated: 07/31/17

Current Funding Opportunities

The Requests for Applications (RFAs) and Program Announcements (PAs) listed below communicate CDP’s current funding opportunities and research interests. CDP staff contacts and published notices are provided in the summary link for each opportunity. We encourage you to discuss your proposed research with a CDP program director before you submit an application. This page updates to reflect the active Funding Opportunities.

To receive email updates, click here or follow us on Twitter.

Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01): PAR-17-003

Posted date: October 4, 2016; Expiration date: October 29, 2019
Application receipt dates: February 28, 2017; July 11, 2017; February 27, 2018; July 11, 2018; October 26, 2018; February 27, 2019; July 11, 2019; October 28, 2019, by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this FOA is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response to treatment, as well as markers for cancer control and prevention. Research applications may support acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

CDP contact: Dr. Kelly Kim, 240-276-7811, kimke@mail.nih.gov

Integrating Biospecimen Science Approaches into Clinical Assay Development (U01): PAR-16-166

Posted date: April 5, 2016; Expiration date: June 23, 2018
Application receipt dates: June 22, 2016; February 13, 2017; October 11, 2017, by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development due to tissue biopsy biospecimen preanalytical variability. The program will tie in with current efforts to optimize clinical biomarker assays utilized in NCI-sponsored clinical trials. Results from this research program will improve the understanding of how biopsy collection, processing, and storage procedures may affect all aspects of analytical performance for current and emerging clinical biomarkers, as well as expedite clinical biomarker assay development through the evidence-based standardization of biopsy handling practices. Critical information gained through these research awards may increase the reliability of clinical biomarker assays, reduce time requirements for assay development, and decrease assay failure during late-stage testing.

CDP contact: Dr. Abhi Rao, 240-276-5715, abhi.rao@mail.nih.gov

Assay Validation For High Quality Markers For NCI-Supported Clinical Trials: PAR-15-095 (UH2/UH3)

Posted date: January 21, 2015; Expiration date: October 7, 2017
Application receipt dates: March 26, 2015; July 8, 2015; October 7, 2015; February 9, 2016; July 8, 2016; October 7, 2016; February 9, 2017; July 7, 2017; October 6, 2017, by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) is a phased initiative to improve the development of molecular diagnostics for use in NCI-supported clinical trials in cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants should have an assay that works in human samples and whose importance is well justified for development into a clinical assay.

CDP contact: Dr. Tracy Lively, 240-276-5944, Livelyt@mail.nih.gov

Revision Applications for Assay Validation For High Quality Markers For NCI-Supported Clinical Trials: PAR-16-056 (U10)

Posted Date: December 10, 2015; Expiration Date: October 7, 2017
Letter of Intent due dates: 30 days prior to the application due date
Application due dates: February 29, 2016; July 8, 2016; October 7, 2016; February 9, 2017; July 7, 2017; October 6, 2017, by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to improve the development and validation of molecular diagnostics for the treatment, control, or prevention of cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants should have an assay that has essentially completed analytical validation in human samples and whose importance is well justified for development into a clinical assay. Revisions may support acquisition of specimens from retrospective or prospective studies from NCI-supported or other clinical trials. Projects proposed for this FOA require multi-disciplinary interaction and collaboration among scientific investigators, clinicians, statisticians and clinical laboratory scientists and staff.

CDP contacts: Dr. Magdalena Thurin thurinm@mail.nih.gov for assays involving immunological diagnostics and non-companion diagnostics for treatment trials and Dr. Tracy Lively livelyt@mail.nih for response, safety, resistance and risk stratification markers for treatment trials.

Assay Validation For High Quality Markers For NCI-Supported Clinical Trials: PAR-15-096 (UH3)

Posted date: January 21, 2015; Expiration Date: October 7, 2017
Application receipt dates: March 26, 2015; July 8, 2015; October 7, 2015; February 9, 2016; July 8, 2016; October 7, 2016; February 9, 2017; July 7, 2017; October 6, 2017, by 5:00 PM local time of applicant organization.

Assays proposed for this FOA may be used to validate existing assays for use in other trials, observational studies or populations. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, clinicians, statisticians and clinical laboratory scientists and staff. Clinical laboratory staff, technical and other needs must be an integral part of the application. This FOA is not intended to support trials that assess the clinical utility of a marker/assay but is intended to develop assays to the point where their clinical utility could be assessed in other trials.

CDP contact: Dr. Tracy Lively, 240-276-5944, Livelyt@mail.nih.gov

Bioengineering Technologies

The NIH bioengineering program supports basic, applied, and translational bioengineering research that addresses important biological or medical research problems.

CDP contact: Mr. Miguel Ossandon: 240-276-5714, ossandom@mail.nih.gov

Exploratory/Developmental Bioengineering Research Grants [EBRG]: PA-16-040 (R21)

Release/Posted Date: November 20, 2015; Expiration date: January 8, 2019
Application Receipt Dates: February 16, June 16, October 16

The EBRGs support early bioengineering research. EBRG applications may contain minimal or no preliminary data, and may propose hypothesis-driven, discovery-driven or design-directed research.

Bioengineering Research Grants [BRG]: PAR-16-242 (R01)

Posted Date: May 10, 2016; Expiration date: May 8, 2019 (renewal of PAR-13-137)
Application Receipt Dates: February 5, June 5, October 5

The BRGs support multi-disciplinary research performed in in a single laboratory or by multiple organizations. A BRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research.

Bioengineering Research Partnerships [BRP]: PA-16-116 (U01)

Release/Posted Date: March 2, 2016; Expiration date: January 8, 2019
Application Receipt Dates: May 18, 2016, September 13, 2016, May 18, 2017, September 13, 2017, May 8, 2018, September 13, 2018

The BRPs support large basic, applied, and translational multi-disciplinary research performed by multiple organizations that applies an integrative approach, which includes bioengineering and biomedical/clinical components.

FOR THE LATEST INFORMATION ABOUT NCI INITIATIVES, VISIT
Division of Extramural Activities, National Cancer Institute
http://deainfo.nci.nih.gov/funding.htm

National Institutes of Health
U.S. Department of Health and Human Services